Previous 10 | Next 10 |
- Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet - - Alzheimer’s disease franchise advances: selected lead candidate for anti-tau antibody program; IND submission on ...
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of George Scangos, Ph.D., to its Board of Directors. Scangos has decades...
2023-05-08 12:45:05 ET Voyager Therapeutics ( NASDAQ: VYGR ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is $1.26 (+325.0% Y/Y) and the consensus Revenue Estimate is $52.5M (+7400.0% Y/Y). Over the la...
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced seven data presentations at the upcoming American Society of Gene and Cel...
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report first quarter 2023 financial and operating results before the market opens on T...
2023-04-02 09:32:46 ET Summary Voyager is a preclinical company with multibillion dollar big pharma deals. Its core asset is its TRACER AAV capsid delivery platform. Although the company was in dire straits two years ago, it has nicely recovered. I covered Voyage...
2023-04-02 08:49:17 ET Summary Shares of gene therapy concern Voyager Therapeutics, Inc. have moved up more than 25% in 2023 on a couple of licensing deals. Last month, Novartis exercised an option to license Voyager's novel capsids for use in gene therapy programs against two und...
CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today presented new data from its anti-tau antibody program for Alzheimer’s disease (AD) and from it...
2023-03-12 08:03:25 ET Summary Two new Breakout Stocks for Week 11 with better than 10% short-term upside and Dow 30 Picks. Average cumulative returns for 2023 are +37.6% YTD. The Momentum Gauges® continued negative with bear funds in the Active ETF with over 17% gains this w...
2023-03-07 15:09:22 ET Voyager Therapeutics, Inc. (VYGR) Q4 2022 Earnings Conference Call March 7, 2023 08:30 ET Company Participants Al Sandrock - Chief Executive Officer Todd Carter - Chief Scientific Officer Pete Pfreundschuh - Chief Financial Officer Alle...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...